Cargando…

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

In MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2− advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor grade, bone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnston, Stephen, O’Shaughnessy, Joyce, Martin, Miguel, Huober, Jens, Toi, Masakazu, Sohn, Joohyuk, André, Valérie A. M., Martin, Holly R., Hardebeck, Molly C., Goetz, Matthew P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219718/ https://www.ncbi.nlm.nih.gov/pubmed/34158513 http://dx.doi.org/10.1038/s41523-021-00289-7

Ejemplares similares

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
por: Johnston, Stephen, et al.
Publicado: (2019)

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
por: Toi, Masakazu, et al.
Publicado: (2021)

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
por: Goetz, Matthew P., et al.
Publicado: (2020)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
por: Johnston, Stephen R. D., et al.
Publicado: (2020)

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
por: Di Leo, Angelo, et al.
Publicado: (2018)

Abemaciclib plus fulvestrant in East Asian women with HR+, HER2− advanced breast cancer: Overall survival from MONARCH 2
por: Toi, Masakazu, et al.
Publicado: (2022)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
por: Toi, Masakazu, et al.
Publicado: (2022)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Takahashi, Masato, et al.
Publicado: (2021)

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels
por: Masuda, Norikazu, et al.
Publicado: (2022)

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
por: Sledge, George W., et al.
Publicado: (2019)

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
por: Neven, Patrick, et al.
Publicado: (2021)

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
por: Goetz, Matthew P., et al.
Publicado: (2021)

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
por: Hamilton, Erika, et al.
Publicado: (2022)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
por: Paluch-Shimon, Shani, et al.
Publicado: (2023)

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
por: Inoue, Kenichi, et al.
Publicado: (2021)

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
por: Zhang, Qing Yuan, et al.
Publicado: (2020)

MonarchBase: the monarch butterfly genome database
por: Zhan, Shuai, et al.
Publicado: (2013)

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial
por: Martin, Miguel, et al.
Publicado: (2022)

Monarchs and Medicine
Publicado: (1899)

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
por: Rugo, Hope S., et al.
Publicado: (2023)

Abemaciclib for breast cancer
Publicado: (2020)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Monarch of the flute : the life of Georges Barrère /
por: Toff, Nancy
Publicado: (2005)

Profile of abemaciclib and its potential in the treatment of breast cancer
por: Martin, James M, et al.
Publicado: (2018)

An evaluation of the Monarch chemistry analyser
por: Berry, D. J., et al.
Publicado: (1989)

Clocks, cryptochromes and Monarch migrations
por: Kyriacou, Charalambos P
Publicado: (2009)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2007)

A decade of letrozole: FACE
por: O’Shaughnessy, Joyce
Publicado: (2008)

Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy
por: O’Shaughnessy, Joyce
Publicado: (2020)

In Monarchs, Cry2 Is King of the Clock
por: Robinson, Richard
Publicado: (2008)

The role of abemaciclib in treatment of advanced breast cancer
por: McCartney, Amelia, et al.
Publicado: (2018)

Abemaciclib: A multi-functional radiation modifier
por: Naz, Sarwat, et al.
Publicado: (2019)

Do Healthy Monarchs Migrate Farther? Tracking Natal Origins of Parasitized vs. Uninfected Monarch Butterflies Overwintering in Mexico
por: Altizer, Sonia, et al.
Publicado: (2015)

How the monarch got its spots: Long-distance migration selects for larger white spots on monarch butterfly wings
por: Davis, Andrew K., et al.
Publicado: (2023)

Genome assembly of Danaus chrysippus and comparison with the Monarch Danaus plexippus
por: Singh, Kumar Saurabh, et al.
Publicado: (2021)

The genetics of monarch butterfly migration and warning coloration
por: Zhan, Shuai, et al.
Publicado: (2014)

Density-dependence in the declining population of the monarch butterfly
por: Marini, Lorenzo, et al.
Publicado: (2017)

Aggression Is Induced by Resource Limitation in the Monarch Caterpillar
por: Collie, Joseph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j9nus7e1blqutt3i7u7avfr9mt